Long-term costs of introducing HPV-DNA post-treatment surveillance to national cervical cancer screening in Ireland.

Publication Type:

Journal Article

Source:

Expert review of pharmacoeconomics & outcomes research, p.1-7 (2015)

Abstract:

Co-testing (cytology plus human papillomavirus DNA testing) as part of cervical cancer surveillance in Ireland increases one-time testing costs. Of interest to policy makers was the long-term impact of these costs accompanied by decreases in intensity of recalls for women with no detected abnormalities.